Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$22.38
+0.3%
$20.32
$17.86
$29.62
$1.10B1.97403,156 shs23,290 shs
Seagen Inc. stock logo
SGEN
Seagen
$228.74
$228.74
$123.77
$228.96
$42.93B0.321.48 million shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
+7.42%+2.62%+3.72%-0.27%-5.47%
Seagen Inc. stock logo
SGEN
Seagen
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$22.38
+0.3%
$20.32
$17.86
$29.62
$1.10B1.97403,156 shs23,290 shs
Seagen Inc. stock logo
SGEN
Seagen
$228.74
$228.74
$123.77
$228.96
$42.93B0.321.48 million shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
+7.42%+2.62%+3.72%-0.27%-5.47%
Seagen Inc. stock logo
SGEN
Seagen
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.40
Hold$32.0043.00% Upside
Seagen Inc. stock logo
SGEN
Seagen
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BLFS and SGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2026
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
DowngradeStrong-BuyHold
4/20/2026
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
Reiterated RatingSell (D-)
(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$101.66M10.75$0.25 per share90.66$7.72 per share2.90
Seagen Inc. stock logo
SGEN
Seagen
$2.30B18.66N/AN/A$15.10 per share15.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$4.59M-$0.08N/A89.51N/A-2.80%1.81%1.65%8/6/2026 (Estimated)
Seagen Inc. stock logo
SGEN
Seagen
-$610.31M-$4.01N/AN/AN/A-32.61%-28.06%-20.92%N/A

Latest BLFS and SGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$0.01$0.04+$0.03$0.02$25.66 million$27.50 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/A
7.30
5.50
Seagen Inc. stock logo
SGEN
Seagen
N/A
2.67
2.12

Institutional Ownership

CompanyInstitutional Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
Seagen Inc. stock logo
SGEN
Seagen
84.26%

Insider Ownership

CompanyInsider Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.20%
Seagen Inc. stock logo
SGEN
Seagen
25.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
44048.86 million47.78 millionOptionable
Seagen Inc. stock logo
SGEN
Seagen
3,256187.70 million139.08 millionNo Data

Recent News About These Companies

Merck in "advanced talks" for $40bn Seagen bid; report
Seagen posts breast cancer win ahead of Pfizer takeover
Is Merck planning a $30bn-plus move for Seagen?
Pfizer raises guidance as COVID franchise drives Q3 beat
Franklin Biotechnology Discovery C
Seagen wins Enhertu patent dispute with Daiichi Sankyo
Pfizer: Turning The Corner (Rating Upgrade)
HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn
MRNA Feb 2024 64.000 put
MRNA Feb 2024 77.000 call
MRNA Feb 2024 67.000 put

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioLife Solutions stock logo

BioLife Solutions NASDAQ:BLFS

$22.38 +0.08 (+0.35%)
As of 10:13 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Seagen stock logo

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.